Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term prostate. Found 26 abstracts

no pagination
Galvao DA, Newton RU, Girgis A, Lepore SJ, Stiller A, Mihalopoulos C, Gardiner RA, Taaffe DR, Occhipinti S, Chambers SK. Randomized controlled trial of a peer led multimodal intervention for men with prostate cancer to increase exercise participation. Psychooncology. 2018 Jan;27(1):199-207.
Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM. Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE. J Urol. 2014 Apr;191(4):971-6.   PMCID: PMC5480381
Makhov P, Golovine K, Canter D, Kutikov A, Simhan J, Corlew MM, Uzzo RG, Kolenko VM. Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. The Prostate. 2012 May;72(6):661-7.   PMCID: PMC3208085
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW. Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 2012 Nov;21(11):2087-94.   PMCID: PMC3493821
Giri VN, Ruth K, Hughes L, Uzzo RG, Chen DY, Boorjian SA, Viterbo R, Rebbeck TR. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU international. 2011 Feb;107(3):466-70.   PMCID: PMC3052292
Makhov P, Kutikov A, Golovine K, Uzzo RG, Canter DJ, Kolenko VM. Docetaxel-Mediated Apoptosis in Myeloid Progenitor TF-I Cells Is Mitigated by Zinc: Potential Implication for Prostate Cancer Therapy. The Prostate. 2011 Sep;71(13):1413-9.   PMCID: PMC3106130
Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prevention Research. 2011 Sep;4(9):1401-8.   PMCID: PMC3172691
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival. Journal of Urology. 2009 Dec;182(6):2708-14.
Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Liao KJ, Schwartz JS, Pollack CE, Wong YN, Armstrong K. Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate Cancer. Medical Care Research and Review. 2009 Aug;66(4):409-35.   PMCID: PMC2780425
D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1082-7.
Bruner DW, Jones M, Buchanan D, Russo J. Reducing cancer disparities for minorities: A multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(14):2209-15.
Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Aug;65(5):1487-93.
Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. Journal of Urology. 2005 Mar;173(3):797-802.
Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005 Sep;24(38):5868-77.
Katz ML, Ruzek SB, Miller SM, Legos P. Gender differences in patients needs and concerns to diagnostic tests for possible cancer. Journal of Cancer Education. 2004 Jan;19(4):227-31.
Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the fox chase experience. Journal of Urology. 2004 Mar;171(3):1132-6.
Iyer RV, Hanlon AL, Pinover WH, Hanks GE. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy. Cancer. 1999 Apr 15;85(8):1816-21.
Green GA, Hanlon AL, Al-Saleem T, Hanks GE. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer. 1998 Sep;83(5):971-6.
Movsas B, Hanlon AL, Pinover W, Hanks GE. Is there an increased rise of second primaries following prostate irradiation?. International Journal of Radiation Oncology Biology Physics. 1998 May;41(2):251-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term prostate

prostate cancer prostatic neoplasms radiotherapy follow-up radiation therapy trial antigen PSA recurrence therapy mortality prostate-specific antigen women Oncology RADICAL PROSTATECTOMY lung CARCINOMA radiation-therapy screening apoptosis radical prostatectomy risk docetaxel prevention & control neoplasm recurrence ESCALATION biopsy chromosome-10 prostatectomy ETHNIC BREAST-CANCER Nuclear Medicine & Medical Imaging Radiology prevention therapeutic radiology radiology progression disparities enrollment DISABILITY GRADE piperine multivariate-analysis Male term follow-up MEN implant AGE prostate carcinoma EORTC KeyWords Plus: target comorbidity TRAIL uptake randomized-trial care information RACIAL oncology fusion administrative data ERA drug-interactions communication secondary neoplasms antigen era nude-mice community metabolism Folic Acid Gleason score adenocarcinoma assessment program doubling time transporter factor-kappa-b specific antigen dose-response relationship failure epidemiology coping style oncology consensus definition risk assessment association Middle Aged Gleason pattern morbidity RANDOMIZED-TRIAL glycoprotein randomized clinical-trial acceptance BLACK prognostic factors 5 genetic-variants Local Neoplasm Recurrence PROGNOSTIC-SIGNIFICANCE survival analysis imaging tissues Prostatic Neoplasms HEALTH peer support group INCREASED FAILURE dose-rate brachytherapy vitro algorithms dosimetry in-vitro radiation- genetics Prospective Studies Medicare exercise american society recruitment strategies african-americans reducing salpingo-oophorectomy local Adenocarcinoma RADIATION-THERAPY selenium PERINEURAL INVASION retention prognostic-factors CONFORMAL RADIATION-THERAPY brachytherapy mesothelin colposcopy biomarker panels expression serum ca-125 levels checkpoint-deficient external-beam radiotherapy Gleason grade carcinoma disease progression androgen deprivation zinc staging participation disease randomized diagnostic performances cycle arrest ALL-CAUSE MORTALITY abiraterone acetate american-society inhibition barriers
Last updated on Friday, January 03, 2020